Efficacy outcomes
With a median follow-up of 9.6 months, the ORR was 83% (10 of 12 patients in the PPS; 95% CI 51.6–97.9; Fig. Response rates by IRC (per protocol set). Overall response and duration of treatment. Progression-free survival (full analysis set). Overall survival (full analysis set)